This activity is intended for obstetricians/gynecologists/women's health clinicians, family medicine/primary care practitioners, cardiologists, nurses, physician assistants, internists, and other members of the health care team involved in screening for hypertensive disorders of pregnancy.
The goal of this activity is that learners will be better able to screen for hypertensive disorders of pregnancy and identify future risks associated with prior hypertensive disorders of pregnancy.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 6/10/2023. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 6/10/2022
Valid for credit through: 6/10/2023, 11:59 PM EST
processing....
Chronic and gestational hypertension, preeclampsia, eclampsia, and other hypertensive disorders of pregnancy are associated with increased risk for future CVD, largely mediated through development of traditional CVD risk factors, including chronic hypertension, diabetes, and obesity.
Women with vs without histories of preeclampsia have twice the CVD risk and 75% increased risk for subsequent CVD mortality. US rates of hypertensive disorders of pregnancy are increasing--nearly doubling from 1993 to 2014--going from 528.9 to 912.4 cases per 10,000 delivery hospitalizations.
Nearly three quarters of clinicians reported screening patients for hypertensive disorders of pregnancy, but only one quarter comprehensively identified cardiovascular risk, according to survey data from approximately 1,500 clinicians in the United States.
Rates of hypertensive disorders of pregnancy have been on the rise in the United States for the past decade, and women with a history of these disorders require cardiovascular risk monitoring during the postpartum period and beyond, write Nicole D. Ford, PhD, from the Centers for Disease Control and Prevention, Atlanta, Georgia, and colleagues. Specifically, the American College of Obstetricians and Gynecologists recommends cardiovascular risk evaluation and lifestyle modification for these individuals, the researchers said.
The most effective management of women with a history of hypertensive disorders of pregnancy will likely involve a team effort by primary care clinicians, obstetrician-gynecologists, and cardiologists, but data on clinician screening and referrals are limited, they added.
In a study published in Obstetrics & Gynecology, the researchers reviewed data from a cross-sectional, web-based survey of clinicians practicing in the United States (Fall DocStyles 2020). The study population of 1,502 respondents with complete surveys included 1,000 primary care physicians, 251 obstetrician-gynecologists, and 251 nurse practitioners or physician assistants. Approximately 60% of the respondents were male, and approximately 65% had been in practice for at least 10 years.
Overall, 73.6% of clinicians reported screening patients for a history of hypertensive disorders of pregnancy. The screening rates were highest among obstetrician-gynecologists (94.8%).
However, although 93.9% of clinicians overall correctly identified at least 1 potential risk associated with hypertensive disorders of pregnancy, only 24.8% correctly identified all cardiovascular risks associated with hypertensive disorders of pregnancy listed in the survey, the researchers noted.
Screening rates ranged from 49.0% to 90.8% for pregnant women, 33.5% to 74.5% for postpartum women, 26.3% to 61.4% for nonpregnant reproductive-age women, 20.3% to 44.6% for perimenopausal or menopausal women, and 1.2% to 4.0% for others outside of these categories.
The barriers to referral most often cited were lack of patient follow-through (51.5%) and patient refusal (33.6%). To improve and facilitate referrals, respondents' most frequent resource request was for more referral options (42.9%), followed by patient education materials (36.2%) and professional guidelines (34.1%).
In a multivariate analysis, primary care physicians were more than 5 times as likely to report not screening patients for hypertensive disorders of pregnancy (adjusted prevalence ratio, 5.54); nurse practitioners and physician assistants were more than 7 times as likely (adjusted prevalence ratio, 7.42).
The researchers also found that clinicians who saw fewer than 80 patients per week were almost twice as likely to not screen for hypertensive disorders of pregnancy than those who saw 110 or more patients per week (adjusted prevalence ratio, 1.81).
"Beyond the immediate postpartum period, there is a lack of clear guidance on [cardiovascular disease (CVD)] evaluation and ongoing monitoring in women with history of hypertensive disorders of pregnancy," the researchers write in their discussion. "Recognizing hypertensive disorders of pregnancy as a risk factor for CVD may allow clinicians to identify women requiring early evaluation and intervention," they add.
The study findings were limited by several factors, including potentially biased estimates of screening practices and the potential for selection bias because of the convenience sample used to recruit survey participants, the researchers noted.
However, the results were strengthened by the inclusion of data from several clinician types and the relatively large sample size, and are consistent with those of previous studies, they said. On the basis of the findings, addressing barriers at both the patient and clinician level and increasing both patient and clinician education about the long-term risks of hypertensive disorders of pregnancy might increase cardiovascular screening and subsequent referrals, they conclude.
More Education, Improved Screening Tools Needed"Unfortunately, most CVD risk stratification scores such as the Framingham score do not include pregnancy complications, despite excellent evidence that pregnancy complications increase risk of CVD," said Catherine M. Albright, MD, from the University of Washington, Seattle, in an interview. "This is likely because these scores were developed primarily to screen for CVD risk in men. Given the rising incidence of hypertensive disorders of pregnancy and the clear evidence that this is a risk factor for future CVD, more studies like this one are needed in order to help guide patient and provider education," said Dr Albright, who was not involved in the study.
"It is generally well reported within the [obstetrician-gynecologist] literature about the increased lifetime CVD risk related to hypertensive disorders of pregnancy and we, as [obstetrician-gynecologists], always ask about pregnancy history because of our specialty, which gives us the opportunity to counsel about future risks," she said.
"Women's health [including during pregnancy] has been undervalued and underresearched for a long time," with limited focus on pregnancy-related issues until recently, Dr Albright noted. "This is clear in the attitudes and education of the primary care providers in this study," she said.
A major barrier to screening in clinical practice has been that the standard screening guidelines for CVD (for example, those published by the US Preventive Services Taskforce) have not included pregnancy history, said Dr Albright. "Subsequently, these questions are not asked during routine annual visits," she said. Ideally, "we should be able to leverage the electronic medical record to prompt providers to view a previously recorded pregnancy history or to ask about pregnancy history as a routine part of CVD risk assessment, and, of course, additional education outside of [obstetrician-gynecology] and cardiology is needed," she said.
The clinical takeaway from the current study is that "every annual visit with a person who has been pregnant is an opportunity to ask about and document pregnancy history," Dr Albright said. "After the completion of childbearing, many patients no longer see an [obstetrician-gynecologist], so other providers need to feel comfortable asking about and counseling about risks related to pregnancy complications," she added.
"It is clear that adverse pregnancy outcomes pose lifetime health risks," said Dr Albright. "We will continue to look into the mechanisms of this through research. However, right now the additional research that is needed is to determine the optimal screening and follow-up for patients with a history of hypertensive disorders of pregnancy, as well as to examine how existing CVD-screening algorithms can be modified to include adverse pregnancy outcomes," she emphasized.
The study received no outside funding. The researchers and Dr Albright have disclosed no relevant financial relationships.
Obstet Gynecol. 2022;139(5):898-906.[1]